Polypeptide dimer with high sialic acid content, comprising extracellular domain of alpha subunit of IGE FC receptor, and pharmaceutical composition comprising same
US12409203B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 7, 2020 |
| Grant date | Sep 9, 2025 |
| Priority date | — |
| Expiry date | Aug 8, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A modified IgE Fc receptor having a high content of sialic acid and a pharmaceutical composition contains the modified IgE Fc receptor are disclosed. The polypeptide dimer having a high content of sialic acid not only has excellent safety and persistence in a body as compared with conventionally used anti-IgE antibodies, but also shows strong binding to IgE. Thus, the polypeptide has the advantage of an extended administration cycle. The polypeptide dimer is also an IgE single target substance, and unlike conventional anti-IgE antibodies to which the Fc of IgG1 is applied, does not bind to an Fc gamma receptor. The polypeptide dimer can be usefully used for the prevention or treatment of allergic diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.